- Home
- UCL vs ALGS Comparison
UCL vs ALGS Comparison
Compare UCL & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UCL | ALGS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | Hong Kong | United States |
| Employees | 429 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.0M | 39.9M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | UCL | ALGS |
|---|---|---|
| Price | $1.01 | $5.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 10.4K | ★ 130.5K |
| Earning Date | 05-20-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | $11.60 | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $5.12 |
| 52 Week High | $4.19 | $13.69 |
Technical Indicators
Market Signals| Indicator | UCL | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 20.42 | 34.18 |
| Support Level | N/A | N/A |
| Resistance Level | $1.38 | $6.76 |
| Average True Range (ATR) | 0.08 | 0.49 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 5.88 | 4.66 |
Price Performance
Historical ComparisonAbout UCL uCloudlink Group Inc.
Ucloudlink Group Inc is engaged in the provision of data connectivity services and sales of Wi-Fi terminals and data-related products globally. Its uCloudlink cloud SIM platform is designed for shared mobile data connectivity services by allocating the SIM cards remotely and dynamically to users. Ucloudlink's core business is to provide mobile data connectivity services at competitive prices, which it delivers through a range of hardware products and service solutions to its business partners, retail, and enterprise customers. The main hardware terminals offered by the company include portable Wi-Fi terminals, smartphones, and smart-hardware products for international and local mobile data connectivity services. Geographically, it generates maximum revenue from Japan.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.